论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yang Z, Gao X, Wang J, Xu L, Zheng Y, Xu Y
Received 2 November 2017
Accepted for publication 15 December 2017
Published 16 February 2018 Volume 2018:11 Pages 843—849
DOI https://doi.org/10.2147/OTT.S155905
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Aim: Interleukin-33 (IL-33),
belonging to IL-1 family cytokines, has been reported to participate in cancer
growth and metastasis. The clinical values of IL-33 in lung cancer have been
previously investigated. We aimed to elucidate the probable role of IL-33 in
the migration and invasion of lung cancer cells.
Methods: Cell migration and invasiveness were tested by
Transwell assay. Western blotting analysis was performed to detect protein
expression.
Results: We found that IL-33 treatment in human lung A549 cells
dose-dependently enhanced their migratory and invasive ability, accompanied by
elevated expression of matrix metalloproteinase (MMP) 2 and MMP9. Meanwhile,
IL-33-induced cell migration and invasion were significantly abolished by small
interfering RNA-targeting ST2, the specific receptor of IL-33. Furthermore,
IL-33 exposure induced the phosphorylation of AKT. Pretreatment with an AKT
inhibitor LY294002 markedly attenuated IL-33-induced cell migration and
invasion.
Conclusion: IL-33/ST2 promoted the migration and invasiveness of
lung cancer cells through AKT pathway. Our findings strongly suggest that IL-33
may serve as a promising therapeutic strategy for lung cancer.
Keywords: ST2, AKT,
migration, invasion